1,983
Views
1
CrossRef citations to date
0
Altmetric
Letter to the Editor

Clinical, laboratory and genetic features of Erdheim-Chester disease patients: analysis of a retrospective cohort of two reference centers in Latin America

ORCID Icon, , , , &

References

  • Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi:10.1182/blood-2016-01-643569.
  • Goyal G, Heaney ML, Collin M, et al. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood. 2020;135(22):1929–1945. doi:10.1182/blood.2019003507.
  • Emile JF, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016;127(22):2672–2681. doi:10.1182/blood-2016-01-690636.
  • Haroche J, Charlotte F, Arnaud L, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012;120(13):2700–2703. doi:10.1182/blood-2012-05-430140.
  • Toya T, Ogura M, Toyama K, et al. Prognostic factors of Erdheim-Chester disease: a nationwide survey in Japan. Haematologica. 2018;103(11):1815–1824. doi:10.3324/haematol.2018.190728.
  • Cao XX, Sun J, Li J, et al. Evaluation of clinicopathologic characteristics and the BRAF V600E mutation in Erdheim-Chester disease among Chinese adults. Ann Hematol. 2016;95(5):745–750. doi:10.1007/s00277-016-2606-1.
  • Haroche J, Cohen-Aubart F, Amoura Z. Erdheim-Chester disease. Blood. 2020;135(16):1311–1318. doi:10.1182/blood.2019002766.
  • Estrada-Veras JI, O'Brien KJ, Boyd LC, et al. The clinical spectrum of Erdheim-Chester disease: an observational cohort study. Blood Adv. 2017;1(6):357–366. doi:10.1182/bloodadvances.2016001784.
  • Roverano S, Gallo J, Ortiz A, et al. Erdheim-Chester disease: description of eight cases. Clin Rheumatol. 2016;35(6):1625–1629. doi:10.1007/s10067-016-3269-y.
  • Melloul S, Helias-Rodzewicz Z, Cohen-Aubart F, et al. Highly sensitive methods are required to detect mutations in histiocytosis. Haematologica. 2019;104(3):e97–e99. doi:10.3324/haematol.2018.201194.
  • Arnaud L, Hervier B, Neel A, et al. CNS involvement and treatment with interferon are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood. 2011;117(10):2778–2782. doi:10.1182/blood-2010-06-294108.
  • Cao XX, Niu N, Sun J, et al. Clinical and positron emission tomography responses to long-term high-dose interferon-α treatment among patients with Erdheim-Chester disease. Orphanet J Rare Dis. 2019;14(1):11), Published 2019 Jan 10. doi:10.1186/s13023-018-0988-y.
  • Diamond EL, Subbiah V, Lockhart AC, et al. Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase; 2, open-label VE-BASKET. Study [published correction appears in JAMA Oncol. 2019 Jan 1;5(1):122]. JAMA Oncol 2018;4(3):384–388. doi:10.1001/jamaoncol.2017.5029.
  • Cohen-Aubart F, Emile JF, Carrat F, et al. Phenothypes and survival in Erdheim-Chester disease: results from a 165-patient cohort. Am J Hematol. 2018;93(5):E114–E117. doi:10.1002/ajh.25055.